Longeveron Announces Board of Directors Planned Transitions
May 10, 2024 16:05 ET
|
Longeveron
Longeveron announces planned transitions on its Board of Directors.
Open Space Institute Holds 50th Anniversary Gala Honoring Founders John & Patricia Adams and Longtime President & CEO Kim Elliman
May 10, 2024 12:47 ET
|
Open Space Institute
New York, NY, May 10, 2024 (GLOBE NEWSWIRE) -- More than 500 guests joined the Open Space Institute (OSI) at the American Museum of Natural History in New York City on Wednesday, May 8th to...
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
May 10, 2024 09:35 ET
|
Immix Biopharma, Inc.
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to...
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 10, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
May 10, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies...
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024 08:00 ET
|
Prime Medicine, Inc.
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- --...
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
May 10, 2024 07:00 ET
|
Century Therapeutics, Inc.
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE)Preclinical...
Humacyte First Quarter 2024 Financial Results and Business Update
May 10, 2024 07:00 ET
|
Humacyte, Inc
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43...
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024 07:00 ET
|
Akero Therapeutics Inc.
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and...
TAR-200-Monotherapie zeigt vollständige Ansprechrate von über 80 Prozent bei Patienten mit nicht-muskelinvasivem Hochrisiko-Harnblasenkarzinom
May 10, 2024 06:44 ET
|
Janssen Cilag International NV
Neue Daten aus der Phase-IIb-Studie SunRISe-1 zeigen schnelles Erreichen eines vollständigen Ansprechens (Complete Response, CR) mit 98 Prozent der Patienten, die innerhalb von 12 Wochen eine CR...